Cargando…
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies
BACKGROUND: We assessed the maximum tolerated regimen (MTR) and dose-limiting toxicities of pazopanib and lapatinib in combination with weekly paclitaxel, and the effect of pazopanib and lapatinib on paclitaxel pharmacokinetics. METHODS: Patients received intravenous paclitaxel on days 1, 8, and 15...
Autores principales: | Tan, A R, Dowlati, A, Stein, M N, Jones, S F, Infante, J R, Bendell, J, Kane, M P, Levinson, K T, Suttle, A B, Burris III, H A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037836/ https://www.ncbi.nlm.nih.gov/pubmed/24800949 http://dx.doi.org/10.1038/bjc.2014.233 |
Ejemplares similares
-
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012) -
Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer
por: McCorkle, J. Robert, et al.
Publicado: (2021) -
Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma
por: Fruehauf, John P., et al.
Publicado: (2018) -
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
por: Suttle, A B, et al.
Publicado: (2014) -
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
por: Suttle, A B, et al.
Publicado: (2014)